Barclays PLC Acquires 100,678 Shares of Neumora Therapeutics, …

Dec 28, 2024 · The institutional investor owned 129,210 shares of the company’s stock after acquiring an additional 100,678 shares during the period. Barclays PLC’s holdings in Neumora Therapeutics were ...

9%
OFF

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired By …

2 weeks from now

Dec 28, 2024 · Barclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 352.9% in the 3rd quarter, according to its most recent filing with the SEC. …

marketbeat.com

9%
OFF

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired By …

2 weeks from now

Dec 28, 2024 · Barclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA – Free Report) by 352.9% in the 3rd quarter, according to its most recent filing with the SEC. …

defenseworld.net

9%
OFF

Neumora Therapeutics (NMRA) News Today - MarketBeat

2 weeks from now

Jan 8, 2025 · Barclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 352.9% in the 3rd quarter, according to its most recent filing with the SEC. …

marketbeat.com

9%
OFF

Neumora Therapeutics' (NMRA) Buy Rating Reaffirmed At

2 weeks from now

Jan 2, 2025 · Barclays PLC boosted its holdings in Neumora Therapeutics by 352.9% during the third quarter. Barclays PLC now owns 129,210 shares of the company's stock worth …

marketbeat.com

$1708000
OFF

Research Analysts Offer Predictions For NMRA FY2024 Earnings

2 weeks from now

Nov 17, 2024 · Barclays PLC now owns 129,210 shares of the company’s stock worth $1,708,000 after purchasing an additional 100,678 shares in the last quarter. Wexford Capital LP raised its …

americanbankingnews.com

000%
OFF

Neumora Therapeutics Aktie (A3EVX4,US6409791000) | Kurs

2 weeks from now

Jan 8, 2025 · Neumora Therapeutics, Inc. (NMRA): Strong Buy with 1,000% Upside Potential

finanzen100.de

$1708000
OFF

Neumora Therapeutics’ (NMRA) Buy Rating Reiterated At

2 weeks from now

Nov 16, 2024 · Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 after purchasing an additional 100,678 shares during the period. Wexford Capital …

techdows.com

9%
OFF

Neumora Therapeutics Target Of Unusually High Options Trading …

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its holdings in Neumora Therapeutics by 352.9% in the 3rd quarter. Barclays PLC now owns 129,210 shares of the company’s stock valued at $1,708,000 …

defenseworld.net

$1708000
OFF

What Is William Blair's Estimate For NMRA FY2029 Earnings?

2 weeks from now

Jan 6, 2025 · Barclays PLC now owns 129,210 shares of the company's stock valued at $1,708,000 after acquiring an additional 100,678 shares during the last quarter. Geode Capital …

marketbeat.com

4%
OFF

Barclays PLC Has $1.70 Million Position In Eagle Bancorp, Inc.

2 weeks from now

Dec 28, 2024 · Barclays PLC boosted its holdings in Eagle Bancorp, Inc. (NASDAQ:EGBN – Free Report) by 29.4% during the third quarter, according to the company in its most recent filing …

etfdailynews.com

$1708000
OFF

Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3

2 weeks from now

Dec 24, 2024 · Barclays PLC now owns 129,210 shares of the company's stock worth $1,708,000 after buying an additional 100,678 shares during the last quarter. Geode Capital Management …

marketbeat.com

4%
OFF

Barclays PLC Acquires 136,541 Shares Of Relay Therapeutics, Inc ...

2 weeks from now

Dec 28, 2024 · Barclays PLC lifted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 118.4% in the 3rd quarter, according to its most recent filing with the Securities and …

defenseworld.net

9%
OFF

Stock Traders Buy Large Volume Of Call Options On Neumora …

2 weeks from now

Jan 6, 2025 · Barclays PLC raised its stake in Neumora Therapeutics by 352.9% during the 3rd quarter. Barclays PLC now owns 129,210 shares of the company's stock worth $1,708,000 …

marketbeat.com

6%
OFF

IShares MSCI EAFE Small-Cap ETF (NASDAQ:SCZ) Shares Sold By …

2 weeks from now

Dec 28, 2024 · Barclays PLC decreased its stake in shares of iShares MSCI EAFE Small-Cap ETF (NASDAQ:SCZ – Free Report) by 82.6% during the third quarter, according to its most …

etfdailynews.com

FAQs about Barclays PLC Acquires 100,678 Shares of Neumora Therapeutics, … Coupon?

Who owns neumora Therapeutics?

Point72 Asset Management L.P. bought a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at about $1,097,000. Finally, Callan Capital LLC grew its position in shares of Neumora Therapeutics by 222.6% in the 2nd quarter. ...

Did hedge funds buy neumora Therapeutics (NMRA)?

Several hedge funds and other institutional investors have recently bought and sold shares of NMRA. Geode Capital Management LLC lifted its stake in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. ...

Does Charles Schwab own neumora Therapeutics?

Charles Schwab Investment Management Inc. lifted its position in shares of Neumora Therapeutics by 139.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock valued at $9,224,000 after buying an additional 406,891 shares during the last quarter. ...

Should you buy neumora Therapeutics (NMRA)?

The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. NMRA has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a research note on Friday. ...

When did neumora Therapeutics (NMRA) last report earnings?

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the previous year, the company posted ($1.14) EPS. ...

Did large investors change their positions in neumora Therapeutics?

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Neumora Therapeutics by 139.7% in the third quarter. ...